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Context: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising
prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of
metastatic disease on computed tomography and bone scan. Given recent drug approvals for
nmCRPC, withmany other therapeutics and imagingmodalities being developed, management of
nmCRPC is a rapidly evolving field that merits detailed investigation.
Objective: To review current nmCRPC management practices and identify opportunities for
improving care of nmCRPC patients.
Evidence acquisition: A literature search up to July 2018 was conducted, including clinical trials
and clinical practice guidelines (National Comprehensive Cancer Network, European Society for
MedicalOncology, EuropeanAssociationofUrology, ProstateCancer[12_TD$DIFF] Clinical TrialsWorkingGroup,
Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence). Keywords
includedprostate cancer, nonmetastatic, castration resistance, risingPSA, andbiochemical relapse.
Evidence synthesis: Recommendations regarding indications for, and frequency of, imaging
and PSA testing, as well as[13_TD$DIFF] for initiating systemic therapy in nmCRPC are based on PSA rise
kinetics and symptoms. Both enzalutamide and apalutamide have been shown to significantly
increase metastasis-free survival in phase III placebo-controlled randomised trials in nmCRPC
patients with PSA doubling time (DT)10mo. The expected impact of new imaging techniques
in the assessment of nmCRPC is also reviewed.
Conclusions: nmCRPC is a heterogeneous disease;while observationmaybe anoption for some
patients, enzalutamide and apalutamide may be appropriate to treat nmCRPC patients with
PSA-DT 10 mo. The emergence of more accurate imaging modalities as well as circulating
tumour biomarker assays will likely redefine the assessment of nmCRPC in the near future.
Patient summary: Herein, we review key literature and clinical practice guidelines to sum-
marise the optimal management of patients with prostate cancer and rising prostate-specific
antigen despite castrate testosterone levels, but [14_TD$DIFF]with no evidence of distant metastasis on
traditional imaging. Newdrugs are being developed for this disease setting; novel imaging and
tumour biomarker blood tests are likely to define this disease state more accurately.
© 2018 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creativecom-
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Despite high cure rates after prostatectomy and/or radiation
therapy, a proportion of patients with prostate cancer will
suffer disease relapse. Since Huggins and Hodges [1]
demonstrated the androgen-dependent nature of prostate
cancer in the 1940s, androgen deprivation therapy (ADT)
has become the mainstay for treating advanced disease.
ADT is not curative for patients with metastatic disease, but
usually induces disease regression and prostate-specific
antigen (PSA) declines, which may be sustained for variable
periods of time and is associated with prolongation of life
when used together with radiation in men with high-risk
localised disease. The role of early salvage ADTafter PSA rise
following local treatment is still a topic for debate [2,3], but
if salvage ADT is used in men with biochemical relapse the
disease nearly always re-emerges despite castrate levels of
testosterone, resulting in biological transformation to what
is known as castration-resistant prostate cancer (CRPC);
however, evolution to CRPC can occur before the actual
identification of metastases on conventional imaging.
This review summarises advances in the management of
nonmetastatic CRPC (nmCRPC), including emerging data
from clinical trials and clinical development of novel
imaging techniques. Patients with nmCRPC are asymptom-
atic and have variable life expectancy; hence, careful
consideration must be given to whether the therapeutic
benefit outweighs the risks inherent to that specific therapy
and its ability to improve patient outcome.
2. Evidence acquisition
A literature search for clinical trials and clinical studies up to
July 2018 was conducted, including peer-reviewed publica-
tions available through PubMed and abstracts from major
scientific conferences. Keywords included “prostate can-
cer”, “nonmetastatic”, “castration-resistance”, “rising PSA”,
“biochemical relapse”. The latest versions of the European
Society for Medical Oncology, National Comprehensive
Cancer Network (NCCN), European Association of Urology,
Prostate Cancer Radiographic Assessments for Detection of
Advanced Recurrence (RADAR) and Prostate Cancer Work-
ing Group (PCWG) guidelines were reviewed.
3. Evidence synthesis
3.1. Current definition of nmCRPC
Prostate cancer progression is a continuous process despite
discrete clinical states having been defined to subclassify
the disease for therapeutic interventions, with pragmatic
delineated biological and clinical milestones marking these
transitions [4]. Progression during ADT defines a move to
the castration-resistant [15_TD$DIFF]state, with visualisation of distant
disease by imaging being the landmark for the metastatic
versus the nonmetastatic state.
Currently, themost accepted definition of progression on
ADT is based on PSA increases and follows the PCWG3consensus, primarily intended to define endpoints for
clinical trial design [5]: a 25% increase from the nadir
(considering a starting value of 1.0 ng/ml), with a
minimum rise of 2 ng/ml, in the context of castrate
testosterone values (<50 ng/dl). Guidelines from the
European Association of Urology acknowledge that there
is no accepted universal definition of PSA relapse, but
usually the evidence of two consecutive PSA rises of >0.2
ng/ml are considered suggestive of progression [6]. PSA
progression following ADT can occur prior to the detection
of metastases in the presence of either (1) local recurrence
in the prostate bed after prostatectomy or persistent local
disease after radical radiation therapy, or (2) no detectable
disease in the primary site, no detected involved lymph
nodes by computed tomography (CT)/magnetic resonance
imaging (MRI; lymph nodes 1.5 cm in the short axis in the
pelvis are not considered), or no disease in bone or visceral
organs. While both scenarios technically constitute a
nonmetastatic and castration-resistant state, the term
nmCRPC commonly refers to the latter situation, which
will be the main focus of this review (Fig. 1). It needs to be
noted that the clinical trials discussed [16_TD$DIFF]herein [17_TD$DIFF]included
nmCRPC patients regardless of the presence or absence of
residual or recurrent local disease. The conventional, and
most commonly utilised, diagnostic imaging studies to
define the nmCRPC state include technetium-99m dipho-
sphonate scintigraphy (bone scan [BS]) for evaluating
skeletal metastases, as well as CT of the chest, abdomen,
and pelvis (or MRI if CT scanning is contraindicated); the
potential role of more sensitive imaging modalities includ-
ing prostate-specific membrane antigen (PSMA) positron
emission tomography (PET) and whole-body MRI is
discussed later in this manuscript.
Optimal disease monitoring in patients suffering from
nmCRPC also remains controversial in routine clinical
practice, with variable imaging re-evaluation strategies
[6–9]. A consensus statement by the RADAR group
suggested pursuing further BS and CT scan when the PSA
level reaches 2 ng/ml, and, if this was negative, recom-
mended repeating these again when the PSA level reaches
5 ng/ml and then again after every doubling of the PSA,
based on PSA testing every 3 mo for asymptomatic men.
They also recommended that this frequency should be
altered for symptomatic patients, in whom clinical evolu-
tion should guide investigations regardless of PSA level [10].
Baseline PSA level, PSA velocity, and PSA doubling time
(PSA-DT) have been associated with time to bone metasta-
ses, and bone metastasis-free survival (MFS) and overall
survival (OS) from nmCRPC [11]; these parameters are
commonly used to decide which nmCRPC patients should
undergo imaging studies and the frequency of these.
3.2. Emerging options for systemic therapy
Prior to the recent prospective trials reported in 2018, it was
estimated that one in three patients with nmCRPC would
develop metastasis within 2 [18_TD$DIFF]years of diagnosis, with
baseline PSA and PSA rise kinetics independently predicting
the risk of detection of metastasis [11]. The median survival
[(Fig._1)TD$FIG]
Fig. 1 – Schematic representation of disease evolution patterns to the clinical states of nonmetastatic castration-resistant prostate cancer (nmCRPC).
ADT = androgen deprivation therapy; BS = bone scintigraphy; CT = computerised tomography; HNPC = hormone-naïve prostate cancer; CRPC = castration-
resistant prostate cancer; mCRPC = metastatic castration-resistant prostate cancer; PC = prostate cancer; PSA = prostate specific antigen.
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by the recent introduction of multiple life-extending
therapies for mCRPC (abiraterone, enzalutamide, radium-
223, and taxanes) and is nowadays probably beyond 4–5 yr
based on the control arms of recent studies [12,13]. In recent
years, several clinical trials have established the benefit of
utilising abiraterone acetate and enzalutamide in earlier
stages of disease [14–17]. As a result, both compounds are
now used regularly in the prechemotherapy mCRPC state,
with abiraterone recently being shown to also significantly
impact the prognosis of patients with metastatic hormone-
naïve prostate cancer. These data supported the evaluation
of these drugs also in the nmCRPC setting.
3.2.1. Landmark trials in nmCRPC: PROSPER and SPARTAN
The evaluation of enzalutamide in the nmCRPC stage has
recently achieved a significant milestone with the report of
randomised phase III trial data. In a previous phase II study,
396 patients with either metastatic (n = 257) or nonmeta-
static (n = 130) CRPC were randomised to receive enzalu-
tamide or bicalutamide at progression on ADT. Among
nmCRPC patients, the hazard ratio (HR) for radiological
progression was 0.24 (95% confidence interval [CI] 0.10–
0.56) favouring enzalutamide. Overall, 87.8% of nmCRPC
patients were free [19_TD$DIFF]of radiological progression after 2 [18_TD$DIFF]years
of enzalutamide therapy [18]. This was followed by a phase
III, double-blind, randomised study of enzalutamide in
nmCRPC (PROSPER) in 1401 patients (randomised 2:1 to
enzalutamide:placebo; median PSA-DT [20_TD$DIFF] prior to study
entry = 3.6 mo) progressing on ADT with PSA-DT of 10
mo. Enzalutamide treatment resulted in significantly
superior[21_TD$DIFF]metastasis-free survival [22_TD$DIFF](MFS [23_TD$DIFF]) (primary endpoint;
median 36.6 mo for enzalutamide vs 14.7 mo for placebo;
HR = 0.29; p < 0.0001; Table 1). These data led to the
approval of enzalutamide by the Food and Drug Adminis-
tration (FDA) for nmCRPC with PSA-DT of 10 mo in July
2018. In a preliminary analysis, differences in OS were notsignificant (HR = 0.80, 95% CI 0.58–1.09, p = 0.15; median
follow-up 22 mo); further analysis of more mature[24_TD$DIFF] survival
data are planned [19].
Apalutamide (ARN-509) was the first drug approved by
the FDA for nmCRPC. Initially, a phase II single-arm study
first evaluated apalutamide (a nonsteroidal androgen
receptor [AR] inhibitor) in CRPC, including 51 nmCRPC
patients with a high PSA level of >8 ng/ml and/or PSA-DT
10 mo. A majority of these cases (80%) were enrolled after
having received ADT and at least one antiandrogen. The
PSA50% response rate (primary endpoint) was 89% [20]. In
2018, a placebo-controlled double-blinded randomised
phase III trial (SPARTAN), enrolling 1207 patients (median
PSA-DT [25_TD$DIFF] prior to study [26_TD$DIFF]entry = 4.5mo, inclusion criteria PSA-
DT10mo), demonstrated superiority for apalutamide over
placebo in MFS (median 40.5 vs 16.2 mo; HR = 0.28;
p < 0.0001). Apalutamide was superior to placebo in all
prespecified secondary endpoints, including time to metas-
tasis, progression-free survival, and time to symptomatic
progression (p < 0.001 for all comparisons). A first survival
analysis showed an HR of 0.7 (95% CI 0.47–1.04, p = 0.07;
median follow-up 20.3 mo) for apalutamide, although
longer follow-up is needed [12].
The 2018 NCCN guideline update already includes the
option of apalutamide as systemic therapy for PSA-DT 10
mo; it needs to be noted that this last update of the NCCN
guidelines preceded the FDA approval of enzalutamide in
this setting. Observation without therapeutic intervention
should also be considered, particularly for PSA-DT10 mo
and/or when the patient is frail or unlikely to benefit due to
limited life expectancy. Alternative secondary hormone
therapy manoeuvres considered by the NCCN guidelines for
patients with rapid PSA-DT include the addition or
withdrawal of first-generation AR inhibitors, and the use
of ketoconazole, corticosteroids, or oestrogens, although
there is a lack of randomised trial data to support that these
interventions would impact patient outcome [7,21].
Table 1 – Comparison of clinical trial design, endpoints, and main results of the two principal trials reported in nmCRPC: SPARTAN and
PROSPER
SPARTAN PROSPER
Trial design Key inclusion criteria  nmCRPC by CT/BS
 Rising PSA
 Testosterone 50 ng/dl
 Baseline PSA 2 ng/ml
 PSA-DT 10 mo
 nmCRPC by CT/BS
 Rising PSA
 Testosterone 50 ng/dl
 Baseline PSA 2 ng/ml
 PSA-DT 10 mo
Stratification factors  PSA-DT >6 vs 6 mo
 Prior use of bone-sparing agents
 Nodal disease (N0 vs N1) at trial entry
 PSA-DT >6 vs 6 mo
 Prior use of bone-sparing agents
Primary endpoint MFS, defined as time from randomisation to
the first detection of distant metastasis on
imaging or death from any cause
MFS, defined as time from randomisation to
radiographic progression or death within 112 d of
treatment discontinuation
Key secondary endpoints Time to metastasis, PFS, PFS2, time to
symptomatic progression, overall survival
Time to PSA progression, time to first use of a new
antineoplastic agent, time to chemotherapy, overall
survival
Population Experimental arm Apalutamide + continued ADT (n = 806)
Median PSA-DT 4.4 mo
Enzalutamide + continued ADT (n = 933)
Median PSA-DT 3.8 mo
Control arm Placebo + continued ADT (n = 401)
Median PSA-DT 4.5 mo
Placebo + continued ADT (n = 468)
Median PSA-DT 3.6 mo
Efficacy Primary endpoint—MFS exper. vs placebo 40.5 vs 16.5 mo
HR 0.28 (95% CI 0.23–0.35), p < 0.001
36.6 vs 14.7 mo
HR 0.29 (95% CI 0.24–0.35), p < 0.001
Time to PSA progression Median not reached for apalutamide group vs
3.7 mo for placebo group
HR 0.06 (95% CI 0.05–0.08)
37.2 vs 3.9 mo
HR 0.07 (95% CI 0.05–0.08), p < 0.0001
Progression-free survival 40.5 vs 14.7 mo




Median not reached for apalutamide group vs
39 mo for placebo group
HR 0.70 (95% CI 0.47–1.04), p = 0.07
Median not reached for either group after median
follow-up time of 22 mo
HR 0.80 (95% CI 0.58–1.09), p = 0.15
ADT = androgen deprivation therapy; BS = bone scan; CI = confidence interval; CT = computed tomography; DT = doubling time; exper. = experiment;
HR = hazard ratio; MFS = metastasis-free survival; nmCRPC = nonmetastatic castration-resistant prostate cancer; PFS = progression-free survival;
PSA = prostate-specific antigen.
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nmCRPC
IMAAGEN was a phase II single-arm trial evaluating the
antitumour activity of abiraterone acetate in nonmetastatic,
post-ADT prostate cancer with rising PSA. With 122 evalu-
able patients, the primary endpoint analysis identified an
87% PSA50% decline rate. Preliminary analysis estimated
that median time to radiographic evidence of disease
progression on abiraterone for nmCRPCwas 41.4mo (95% CI
27–not reached) [22]. No randomised phase 3 trial testing
abiraterone acetate has been conducted in men with
nmCRPC.
The efficacy of darolutamide (ODM-201, BAY-1841788, a
novel AR inhibitor) in men with high-risk nmCRPC is also
being evaluated in the ARAMIS phase III trial
(NCT02200614)— a double-blind, placebo-controlled study
that has now completed accrual.
A single-armphase II trial evaluated orteronel (TAK-700),
a CYP17A inhibitor, in nonmetastatic prostate cancer. The
trial population had short baseline PSA-DT (median 2.4mo),
indicating a high-risk population [23]. Median time to PSA
progression and first detectable metastases were 13.8 and
25.4 mo, respectively, with six of 38 patients meeting the
primary endpoint of PSA 0.2 after 3 mo of therapy [24]. The
development of orteronel was halted after randomised
phase III studies failed to demonstrate prolongation of OS in
the mCRPC state.3.3. Challenges of PSA testing: what does rising PSA really
mean?
PSA is a peptidase and a downstream target gene of AR, and
glucocorticoid receptor, signalling. Curiously, it is neither an
antigen nor prostate specific, being expressed in other
tissues, including the female breast[27_TD$DIFF] gland, at lower
concentrations. In healthy conditions, it is primarily secreted
by epithelial prostate cells, but its transcriptional regulation
by AR makes it a biomarker of AR signalling in tumours,
resulting in its application in prostate cancer management.
Whether PSA is just a messenger or also has a direct impact
on prostate cancer pathogenesis is still unclear.
In the setting of nmCRPC, when no disease is detectable
by conventional imaging tests, PSA testing indirectly
monitors tumour AR signalling activity, which can correlate
with disease burden. However, it must be noted that PSA
declines are not proven surrogate biomarkers of survival
outcome and that downregulation of AR signalling does not
always represent tumour cell elimination, and indeed it is
well recognised that some aggressive prostate cancers are
low PSA secretors [25,26]. In the nmCRPC state, more data
are needed to demonstrate that slowing of PSA velocity, or
achievement of a greater PSA decline in the nmCRPC state, is
associated with meaningful benefit in terms of extending
survival or improving quality of life. In the SPARTAN trial, a
50% PSA decline was associated with a significant reduction
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reported outcomes and health-related quality-of-life ques-
tionnaires [27]. PSA-DT in nmCRPC has, however, been
associated with prognosis; trials evaluating inhibition of
bone turnover with the endothelin antagonist atrasentan
[28] and RANK ligand inhibition with denosumab [29]
evaluated PSA changes in the nmCRPC state and their
association with outcome. Briefly, neither drugs demon-
strated an improvement in OS, although denosumab
significantly prolonged bone-metastasis–free survival
(HR = 0.85 [95% CI 0.73–0.98], p = 0.028) compared with
placebo. In the atrasentan trial, PSA-DT was longer in the
active treatment arm than in the placebo arm (p = 0.031), but
this did not translate into significant prolongation of time to
progression (671 vs 764 d; p = 0.288) orOS (HR = 0.92 [95%CI
0.77–1.10], p = 0.22). Importantly, an analysis of the placebo
arm in the denosumab trial correlated PSA-DT with patient
outcome, identifying a higher relative risk of bonemetastasis
or death for patients with PSA-DT shorter than 8 mo [30].
3.4. Clinical trial endpoints and clinical benefit in nmCRPC
3.4.1. MFS and clinical benefit
Measuring the magnitude of clinical benefit derived from a
therapy in patients with no radiological evidence of
metastatic disease and clinical symptoms has been a major
challenge for developing novel therapeutic strategies in
nmCRPC. The recent PROSPER and SPARTAN trials, as well as
the ongoing ARAMIS trial, have used prolongation of time to
metastatic disease visible by CT and BS as a primary
endpoint (MFS).
The approval granted by the FDA to apalutamide and
enzalutamide in nmCRPC is the first ever based on MFS
benefit in prostate cancer and sets a precedent for a
paradigm change in prostate cancer clinical trials. While
certainly the true clinical benefit of delaying an asymptom-
atic radiographic event is yet to be fully defined, MFS as an
intermediate endpoint supported by secondary analyses
can now be assumed to accelerate FDA approval of prostate
cancer drugs, compared towaiting for the gold-standard OS
data. It remains to be seen whether other regulators will
view MFS in the same light.
When evaluating trials conducted in the adjuvant
setting, an improvement in 5-yr MFS has been shown to
be a surrogate for OS in patients with intermediate- and
high-risk, and clinically localised prostate cancer [31]. How-
ever, these data cannot be extrapolated to nmCRPC.
Conceptually, MFS in the localised hormone-naïve cancer
setting involves prevention of the development of any
metastasis after a therapy with curative intent, but in the
nmCRPC setting, MFS involves delaying of the appearance of
a greater (ie, visible on imaging) burden of established
metastatic disease probably already present but occult due
to insensitive conventional imaging. Exploratory landmark
analysis in patients who developed metastases after 6, 9,
and 12 mo in the SPARTAN trial suggests that an association
between MFS and OS may be also present in nmCRPC
(Spearman's correlation coefficient: 0.62; p < 0.0001) [32],
but determination of OS surrogacy for MFS in nmCRPC willprobably require a meta-analysis of individual patient data
from all nmCRPC phase 3 trials.
Notably,MFSwas associatedwith improvements in health-
relatedqualityof life in sevenof 10 scoring systemsanalysed in
the PROSPER study [27]. Apalutamide also resulted in a 55%
reduction in the risk of symptomatic progression (skeletal
events, pain progression, or other clinically relevant symp-
toms) in the SPARTAN trial. Quality-of-life data after treatment
discontinuation is expected to assesswhetherdelaying time to
metastasis detection associates with significant deferment in
symptom development.
3.4.2. What are the benefits and risks of treating nmCRPC rather
than mCRPC?
An unmet need in clinical trials for nmCRPC is evaluating
not only the clinical benefits of an intervention, but also the
additional benefit derived frompursuing such interventions
at the nmCRPC stage rather than at a later time point. The
implications of treatment intensification in the asymptom-
atic nmCRPC stage also need to account particularly for the
long-term toxicities of earlier and therefore longer drug
administration, as well as the associated economic implica-
tions. In the PROSPER study, 5% and 3% of patients in the
enzalutamide cohort suffered grade 3 hypertension and
fatigue, respectively, compared with 2% and 1% in the
placebo group. In the SPARTAN trial, grade 3–4 rash (5.2% vs
0.3%), falls (1.7% vs 0.8%), and fractures (2.7% vs 0.8%) were
more common in the apalutamide arm.
Health-economic issues also need to be considered; there
is an urgent need for studies analysing the impact of earlier
treatment on healthcare costs, taking into consideration
drug costs and the benefits of delaying disease progression,
as well as drug- and disease-related adverse events, and the
economic benefit of improving quality of life. These studies
are necessary but challenging as costs and “willingness-to-
pay” thresholds differ between countries and healthcare
systems. A similar issue is being faced with the recent
successful pivotal trials of abiraterone and docetaxel in the
hormone-naïve metastatic prostate cancer setting [33].
Assessing the impact of earlier versus later intervention can
be fully validated only by conducting prospective trials with
direct comparison of these strategies, where the impact on
survival and quality of life of pursuing the same therapeutic
strategyat nmCRPCormCRPC is compared. In themeantime, a
more mature analysis of OS data from the PROSPER and
SPARTAN trials, where a proportion of patients in the placebo
arms [28_TD$DIFF]received enzalutamide later in the course of the disease
could, at least in part, be informative. For now, the trend
towards an improvement in OS as a supportive secondary
endpoint indicates that[29_TD$DIFF] at least there is no suggestion of
truncation of survival with early use of these agents.
3.4.3. Can we define a concept of “molecular residual disease” or
micrometastatic state using circulating tumour cell counts and
ctDNA? (Anatomical M0 vs biological M0)
Several studies have indicated the prognostic utility of
circulating tumour cell counts, and more recently also of
ctDNA, and the utility of a change in these parameters as a
response biomarker for metastatic prostate cancer
E U RO P E AN URO L OGY 7 5 ( 2 019 ) 2 8 5 – 2 9 3290[34–36]. The burden of circulating tumourmaterial inpatients
with localised prostate cancer seems to be very low with
current detection techniques [37], but if present, detection of
disseminated tumour cells may be associated with a greater
risk of metastatic disease [38]. Identification of “molecularly
detectable residual disease” from circulating tumourmaterial
or bone micrometastasis in nmCRPC could help stratify
nmCRPC patients based on the risk of relapse and for
treatment intensification. A particular challenge for the use of
ctDNA inprostate cancer is the lack of highly recurrent truncal
mutations that would enable very focused assessment (eg,
ctDNA assessment of only KRAS and TP53 in pancreatic
adenocarcinoma).
3.5. New imaging modalities will redefine the classification of
prostate cancer
Clinical trial data for nmCRPC also have to be interpreted in
light of the diagnostic tools used to classify patients as
[(Fig._2)TD$FIG]
Fig. 2 – Axial section of Ga-68-PSMA-PET (A) identifying a small sacral bone m
detected by CT (B) or bone scan. (C) PET/CT fusion images, with the arrow poin
PET = positron emission tomography; PSA = prostate specific antigen; PSMA = pnonmetastatic. The current standard imaging techniques for
evaluation of distant metastasis in patients with rising PSA
are CT and BS, and these have limited accuracy to detect
prostate cancer dissemination to lymph nodes and bone. CT
has limited sensitivity for the detection of metastatic lymph
nodes (42% [95% CI 26–56%] in a pooled analysis of
18 clinical studies) [39]. A recent meta-analysis has shown
that BS has a sensitivity of 79% and specificity of 82% for
detecting bone metastases at single-patient level [40]. De-
velopment of more sensitive molecular and functional
imaging is likely to help define the true extent of disease,
detect small foci of [4_TD$DIFF] relapse, and shrink the size of the true
nmCRPC population. It is critical that more sensitive
imaging assays undergo the same level of scrutiny as
predictive biomarker and drug development strategies to
enable their clinical qualification. Critically, the clinical
relevance of identifying metastatic lesions not detected by
CT and BS requires further evaluation in clinical trials as
axioms from nmCRPC trials cannot be extrapolated if theetastasis in a patient with rising PSA on ADT with no metastatic disease
ting at the metastatic deposit. CT = computed tomography;
rostate-specific membrane antigen.
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sensitive imaging modalities (eg, PSMA PET and whole-
body MRI).
Pelvic multiparametric magnetic resonance imaging
(mpMRI) with anatomical and functional sequences is also
changing traditional approaches to prostate cancer diagno-
sis [41] and is more sensitive at detecting local relapse after
radical prostatectomy [42]. For the detection of distant
metastases in the nmCRPC setting, whole-body coverage
may be needed. Whole-body MRI is more sensitive at
detecting bone metastases than BS and CT approaches
[43]. Diffusion-weighted imaging (DWI) is a functional MRI
technique studying the random movement of water
molecules within a tissue; DWI with whole-body MRI
accurately depicts disease in solid organs with high
sensitivity for bone metastasis detection [44], although
this is less sensitive in detecting the involvement of small
lymph nodes.
PET with awide variety of radiopharmaceuticals has also
been utilised to assess nodal and bone infiltration by
prostate cancer. The most commonly used radiopharma-
ceutical for any type of cancer assessment, 18 [11_TD$DIFF] -fluorodeox-
yglucose (FDG), performs poorly in metastatic prostate
cancer detection probably due to the lack of glucose avidity
in hormone-sensitive and/or small prostate cancer lesions
[45]. PET/CT with 11C-choline has been reported to have a
sensitivity of 73% and specificity of 88% for detecting
postprostatectomy, clinically suspected, recurrent disease
[46]. Nevertheless, in a study of patients with rising PSA
after prostatectomy, mpMRI was reported to be superior at
detecting local recurrence, while 11C-choline PET/CT was
superior at detecting pelvic nodal metastases; both were
equally accurate for detecting pelvic bone metastasis [47].
Other PET tracers under evaluation include NaF; F-18-
fluciclovine, more developed in the context of detecting
recurrences for imaging in the hormone-naïve setting [48];
and 68Ga-PSMA. PSMA-PET/CT seems more sensitive than
other radiotracers at detecting metastases, although con-
cerns remain about heterogeneous PSMA expression in
prostate cancers [49–51] (Fig. 2). In retrospective analyses
of 1007 consecutive cases with biochemical recurrence
scanned with 68Ga-PSMA PET/CT, 79.5% had a least one
lesion indicating recurrent disease [52]. The probability of
positive PSMA-PET increased significantly with higher PSA
levels, an association identified in other studies [53]. Only
24% of these patients had previously received ADT. Prior to
direct extrapolation of data to the nmCRPC space, we need
to better understand how AR signalling, ADT, and the
development of castration resistance modulate PSMA
expression, with studies of PSMA-PET/CT in nmCRPC
[54,55].
These novel imaging modalities are increasingly avail-
able to clinicians, primarily in academic centres, but axioms
from recent nmCRPC trials cannot be extrapolated if the
definition of nmCRPC changes. It is critical that the clinical
relevance of identifying metastatic lesions by PET/CT or
whole-body MRI, not detectable by CT and BS, undergoes
proper scrutiny in clinical trials so that these new imaging
modalities are clinically qualified to guide clinical decisions.4. Conclusions
Nonmetastatic CRPC is a heterogeneous state defined by
rising PSA and insensitive imaging. The emergence of
improved imaging including PSMA-PET/CT and whole-body
MRI, and novel circulating tumour biomarker assays can
redefine the prostate cancer [30_TD$DIFF]management landscape.
Interpretation of clinical trial data in this setting will need
to account for this, as past data based on established
imaging cannot be extrapolated to future practice. Apalu-
tamide and enzalutamide have been shown to significantly
increase time to detectable metastases by BS and CT scan.
Although further indicators of clinical benefit are awaited,
these data are impacting the landscape of prostate cancer
care.
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